All In Biotech

Free tool

FAERS Monitor: Arranon

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021877 or its brand name (Arranon, Nelarabine). Reports on generic versions are filed under their own applications.

Reports

974

Serious

937

96% of reports

Hospitalization

329

Death reported

213

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • febrile neutropenia76
  • drug ineffective67
  • neuropathy peripheral63
  • neurotoxicity61
  • peripheral sensory neuropathy56
  • sepsis56
  • muscular weakness55
  • off label use53
  • myelopathy52
  • neutropenia52
  • guillain-barre syndrome42
  • thrombocytopenia41
  • gait disturbance39
  • hypoaesthesia39
  • peripheral motor neuropathy37

Reports by year received

View as table
YearReports
200610
200713
200817
200924
201026
201126
201227
201373
201452
201539
201648
201764
201856
201929
202039
202135
202298
202377
202468
2025116
202637

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,185 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelopathySignal52607.9464.830,060
peripheral motor neuropathySignal37585.9425.320,470
peripheral sensory neuropathySignal56208.9161.811,273
guillain-barre syndromeSignal42189.1140.57,608
neurotoxicitySignal6175.459.14,395
febrile neutropeniaSignal7624.820.01,713
neuropathy peripheralSignal6314.311.3770
sepsisSignal5610.88.4493
muscular weaknessSignal5510.58.1463
neutropeniaSignal528.36.3327
thrombocytopeniaSignal417.95.9242
hypoaesthesiaSignal395.64.1145
gait disturbanceSignal394.43.2100
off label use531.31.04
drug ineffective671.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.